When does vortioxetine go generic?

Short answer: There isn’t a generic vortioxetine (Brintellix/Trintellix) on the U.S. market right now. The timing of a generic depends on patent expirations and regulatory exclusivities, which can shift with litigation or settlements.

Helpful points:
- In the U.S., generic entry usually follows the expiration of the brand’s core patents plus any data or market exclusivities. Vortioxetine’s exact patent expiration dates are listed in the FDA’s Orange Book, and those dates determine when a generic could be approved and sold.
- Because patent terms and possible lawsuits or settlements can change the schedule, the date is not fixed. Most analysts expect generics to appear only after the primary patents expire, which could be several years from now (often late 2020s to early 2030s in many cases), but this is not a guarantee.
- Other countries have their own patent data and regulatory timelines, so the situation can differ by country.
- There may also be authorized generics or other market arrangements even before a true generic entry.

How to check the latest status:
- Look up vortioxetine in the FDA Orange Book (drug patents and exclusivities) for current patent expiration dates and any exclusivities.
- Check for any approved generic versions (ANDA approvals) and related dates.
- If you’re outside the U.S., check your country’s regulator or a local drug database for patent and generic entry dates.

If you tell me your country, I can look up the latest status there and give you a more specific timeline.